Sinergium Biotech S.A.
Sinergium Biotech is an Argentine biopharmaceutical company specializing in the research, development, production, and commercialization of vaccines and high-complexity biopharmaceutical products. It aims to improve health and preserve life through innovative strategies, strategic alliances, and local production of vaccines, including mRNA technology, to reduce dependency on imports and foster regional self-sufficiency. The company is committed to quality, responsibility, efficiency, and innovation, with a vision to be a leader in the supply of high-quality vaccines both locally and internationally.
Industries
Nr. of Employees
large (251-1000)
Sinergium Biotech S.A.
Ruta Panamericana Km 38,7. Garín. CP 1619. Buenos Aires. Argentina
Products
Inactivated hepatitis A vaccine (national supply)
Inactivated hepatitis A vaccine supplied for national immunization programmes.
Intravesical immunotherapy for non‑muscle invasive bladder cancer
Intravesical immunotherapy formulation used as adjuvant treatment to reduce recurrence of superficial urothelial carcinoma after resection.
20‑valent pneumococcal conjugate vaccine (planned local production)
Planned local production of a 20‑valent pneumococcal conjugate vaccine to expand serotype coverage and supply doses for national immunization and regional distribution.
Inactivated hepatitis A vaccine (national supply)
Inactivated hepatitis A vaccine supplied for national immunization programmes.
Intravesical immunotherapy for non‑muscle invasive bladder cancer
Intravesical immunotherapy formulation used as adjuvant treatment to reduce recurrence of superficial urothelial carcinoma after resection.
20‑valent pneumococcal conjugate vaccine (planned local production)
Planned local production of a 20‑valent pneumococcal conjugate vaccine to expand serotype coverage and supply doses for national immunization and regional distribution.
Services
On‑site aseptic fill‑and‑finish services for vaccines and biologics, including prefilled syringe and vial formats and integration with technology transfer projects.
Management and operational delivery of technology transfer projects for vaccine platforms, including partner coordination, training and process replication.
Research, formulation and preclinical testing services for vaccine candidates, including immunogenicity studies and preparation for early clinical development.
Design and implementation of collaborative agreements to enable local production of vaccines and coordinated regional distribution through pooled procurement.
On‑site aseptic fill‑and‑finish services for vaccines and biologics, including prefilled syringe and vial formats and integration with technology transfer projects.
Management and operational delivery of technology transfer projects for vaccine platforms, including partner coordination, training and process replication.
Research, formulation and preclinical testing services for vaccine candidates, including immunogenicity studies and preparation for early clinical development.
Design and implementation of collaborative agreements to enable local production of vaccines and coordinated regional distribution through pooled procurement.
Expertise Areas
- Vaccine development and manufacturing
- mRNA platform development and technology transfer
- Conjugate vaccine process development and scale-up
- Aseptic fill‑and‑finish for syringes and vials
Key Technologies
- mRNA vaccine platforms
- Lipid nanoparticle (LNP) formulation
- Conjugate vaccine manufacturing processes
- Aseptic high-throughput filling
News & Updates
Visit of Medicines Patent Pool (MPP) to Sinergium Biotech
MPP representatives evaluated facilities and collaborated on a plan for mRNA technology transfer, supporting regional vaccine development efforts.
Argentina OPS visit and vaccine cooperation agreement
High-level meetings with government officials, signing of agreements for vaccine production and technology transfer, including the development of PCV20 and hepatitis A vaccines.
Development of regional mRNA vaccine capacity
Collaborations with WHO, OPS, and regional partners to develop and produce mRNA vaccines for pandemic preparedness, including efforts against H5N1 influenza.
Launch of new pneumococcal vaccine (VCN20)
Partnership with Pfizer and OPS to produce and distribute a 20-valent pneumococcal conjugate vaccine, with regional access and regional production in Argentina.
Development of mRNA vaccines against H5N1 influenza
Partnership with WHO and MPP to develop vaccines for avian influenza H5N1, including preclinical studies and plans for new plant construction in Argentina.
Sinergium Biotech and WHO collaboration on mRNA vaccines
Partnership to develop and transfer mRNA technology for COVID-19, influenza, and other diseases, strengthening regional capacity.
Visit of Medicines Patent Pool (MPP) to Sinergium Biotech
MPP representatives evaluated facilities and collaborated on a plan for mRNA technology transfer, supporting regional vaccine development efforts.
Argentina OPS visit and vaccine cooperation agreement
High-level meetings with government officials, signing of agreements for vaccine production and technology transfer, including the development of PCV20 and hepatitis A vaccines.
Development of regional mRNA vaccine capacity
Collaborations with WHO, OPS, and regional partners to develop and produce mRNA vaccines for pandemic preparedness, including efforts against H5N1 influenza.
Launch of new pneumococcal vaccine (VCN20)
Partnership with Pfizer and OPS to produce and distribute a 20-valent pneumococcal conjugate vaccine, with regional access and regional production in Argentina.
Development of mRNA vaccines against H5N1 influenza
Partnership with WHO and MPP to develop vaccines for avian influenza H5N1, including preclinical studies and plans for new plant construction in Argentina.
Sinergium Biotech and WHO collaboration on mRNA vaccines
Partnership to develop and transfer mRNA technology for COVID-19, influenza, and other diseases, strengthening regional capacity.